盐湖城–(BUSINESS WIRE)–(美国商业资讯)– HOYA Vision Care (https://www.hoyavision.com/)今日公布了三项关键临床研究的新临床证据，凸显了多区正向光学离焦(D.I.M.S.)技术的效果。这些成果作为该公司2025年“通过MiYOSMART*探索近视管理新前沿”科学项目的一部分，在美国犹他州盐湖城举行的2025年视觉与眼科研究协会(ARVO)年会上呈报。 全球最长近视管理镜片临床研究的最新发现显示，在整整8年(n=11)的随访期内，持续…
Author: Business Wire
HOYAビジョンケア、眼科と視覚に関する研究会議（ARVO）の2025年年次総会で最新情報を発表
ソルトレイクシティ–(BUSINESS WIRE)–（ビジネスワイヤ） — HOYAビジョンケア（https://www.hoyavision.com/）はDIMA技術の影響を浮き彫りにする3つの臨床試験から得られた新しいエビデンスを発表 しました。本結果は、ユタ州ソルトレイクシティで開催された2025年視覚と眼科学研究協会（ARVO）年次総会において、同社の2025年科学プログラム「MiYOSMART*による近視管理の新たなフロンティアの探求」の一環として発表されました。 近視管理用眼鏡レン…
HOYA Vision Care onthult updates van de jaarlijkse bijeenkomst van de Association for Research in Vision and Ophthalmology (ARVO) 2025
SALT LAKE CITY–(BUSINESS WIRE)–HOYA Vision Care (https://www.hoyavision.com/) heeft vandaag nieuw klinisch bewijs aangekondigd uit drie belangrijke klinische studies die de impact van Defocus Incorporated Multiple Segments (D.I.M.S.)-technologie bena…
HOYA Vision Care informiert über Neuigkeiten von dem Jahreskongress 2025 der Association for Research in Vision and Ophthalmology (ARVO)
SALT LAKE CITY–(BUSINESS WIRE)–HOYA Vision Care ( https://www.hoyavision.com/) hat heute neue klinische Nachweise aus drei wichtigen klinischen Studien veröffentlicht, die die Wirkung der Defocus Incorporated Multiple Segments (D.I.M.S.)-Technologie …
HOYA Vision Care dévoile les dernières nouvelles de la réunion annuelle 2025 de l'Association for Research in Vision and Ophthalmology (ARVO)
SALT LAKE CITY–(BUSINESS WIRE)–HOYA Vision Care (https://www.hoyavision.com/) a annoncé aujourd’hui de nouvelles preuves cliniques issues de trois études cliniques clés soulignant l’impact de la technologie D.I.M.S. (Defocus Incorporated Multiple Seg…
HOYA Vision Care presenta nuevos hallazgos en la reunión anual de 2025 de la Asociación de Investigación en Visión y Oftalmología (ARVO)
SALT LAKE CITY–(BUSINESS WIRE)–HOYA Vision Care (https://www.hoyavision.com/) presentó hoy los nuevos resultados que arrojaron tres estudios clínicos clave y que destacan el impacto de la tecnología de lentes de desenfoque periférico (DIMS). Los resu…
HOYA Vision Care在2025年視覺與眼科研究協會(ARVO)年會上公布最新研究進展
鹽湖城–(BUSINESS WIRE)–(美國商業資訊)– HOYA Vision Care (https://www.hoyavision.com/)今日公布了三項關鍵臨床研究的新臨床證據，彰顯了多區正向光學離焦(D.I.M.S.)技術的效果。這些成果是該公司2025年「透過MiYOSMART*探索近視管理新尖端」科學計畫的一部分，在美國猶他州鹽湖城舉行的2025年視覺與眼科研究協會(ARVO)年會上呈報。 全球最長近視管理鏡片臨床研究的最新發現顯示，在整整8年(n=11)的隨訪期內，持續佩…
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
SALT LAKE CITY–(BUSINESS WIRE)–HOYA Vision Care (https://www.hoyavision.com/) today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results w…
As mais recentes tecnologias cirúrgicas inovadoras da Alcon, o UNITY® VCS e o UNITY® CS, são aprovadas no Brasil
SÃO PAULO–(BUSINESS WIRE)– #Alcon–A Alcon, líder global em cuidados com a visão dedicada a ajudar as pessoas a verem de forma brilhante, anuncia que o equipamento para cirurgias de retina e vítreo e de catarata (VCS/CS) UNITY®, bem como o equipament…
EyeCare Partners Releases Inaugural Quality and Outcomes Report, Showcasing Impact and Industry-Leading Benchmarks
ST. LOUIS–(BUSINESS WIRE)–EyeCare Partners released its first Quality and Outcomes Report, highlighting achievements in clinical excellence, research and patient outcomes.
Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma
DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and latan…
KiWear Unveils Smart Ring Input Solution for AI Glasses in Collaboration with Qualcomm at AWE USA 2025
LONG BEACH, Calif.–(BUSINESS WIRE)–KiWear, Inc. today announced a reference design for a smart ring input solution for use with smart glasses and AI glasses during Qualcomm Technologies, Inc.’s opening keynote presentation at AWE USA 2025. The collab…
20/20 Onsite Expands Mobile Vision Fleet, Strengthening Nationwide Reach and Clinical Trial Support Capacity
BOSTON–(BUSINESS WIRE)–20/20 Onsite, the leading provider of point-of-need ophthalmic services for clinical trials, announces the deployment of its latest mobile vision clinic, bringing its fleet to 16 units, including a mix of mobile clinics, pods, …
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+L…
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
NASHVILLE, Tenn. & TAIPEI, Taiwan–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby …
Virginia G. Piper Charitable Trust Names Laura Smith as Director of Eyes On Learning
PHOENIX–(BUSINESS WIRE)– #Arizona–Virginia G. Piper Charitable Trust has appointed Laura Smith as the new director of Eyes On Learning, a coalition of state, local, and national organizations dedicated to improving the vision health of Arizona’s chi…
Virginia G. Piper Charitable Trust Names Laura Smith as Director of Eyes On Learning
PHOENIX–(BUSINESS WIRE)– #Arizona–Virginia G. Piper Charitable Trust has appointed Laura Smith as the new director of Eyes On Learning, a coalition of state, local, and national organizations dedicated to improving the vision health of Arizona’s chi…
Samenvatting: Biocytogen en Nanjing Chia Tai Tianqing kondigen IND-goedkeuring aan in China voor het gezamenlijk ontwikkelde anti-IGF-1R antilichaam NTB003 (BCG009)
BEIJING & NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) en Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (“NJCTTQ”) hebben bekendgemaakt dat voor hun gezamenlijk ontwikkelde injecteerbar…
Biocytogen et Nanjing Chia Tai Tianqing annoncent l’autorisation IND en Chine pour l’anticorps anti-IGF-1R NTB003 (BCG009) développé conjointement
PÉKIN et NANJING, Chine–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Pékin) Co., Ltd. (« Biocytogen », HKEX : 02315) et Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (« NJCTTQ ») ont annoncé que le NTB003 (anciennement BCG009), un candidat médica…
Resumen: Biocytogen y Nanjing Chia Tai Tianqing anuncian aprobación IND en China para el anticuerpo NTB003 (BCG009) desarrollado conjuntamente contra el IGF-1R
BEIJING y NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Pekín) Co. Ltd. (“Biocytogen”, HKEX: 02315) y Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (“NJCTTQ”) anunciaron que NTB003 (ex BCG009), un candidato a fármaco inyectable desar…